SCHEMBL6565651

SCHEMBL6565651

COc1ccc2c(c1)C(=NO)C(=O)CC2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.54
MEN1 O00255 1/20 0.54
APP P05067 1/20 0.54
MAPT P10636 1/20 0.54
SNCA P37840 1/20 0.54
KMT2A Q03164 1/20 0.54
MAOB P27338 2/20 0.46
MAOA P21397 1/20 0.45
METAP1 P53582 2/20 0.44
ACHE P22303 1/20 0.44
CYP19A1 P11511 2/20 0.44
MAPK14 Q16539 2/20 0.43
TYMS P04818 1/20 0.43
NQO2 P16083 2/20 0.42
MTNR1A P48039 2/20 0.42
MTNR1B P49286 2/20 0.42
NPC1 O15118 1/20 0.42
LMNA P02545 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL251842 0.82 MAOB (0.54) ALDH1A1MAOBMETAP1ACHECYP19A1
SCHEMBL29392039 0.82 MAOB (0.54) ALDH1A1MAOBMETAP1ACHECYP19A1
SCHEMBL5871789 0.79 MAOB (0.58) ALDH1A1MAOBMAOAMETAP1ACHE
SCHEMBL7272155 0.79 MAOB (0.52) ALDH1A1MEN1APPMAPTSNCA
SCHEMBL7272150 0.79 MAOB (0.52) ALDH1A1MEN1APPMAPTSNCA
Acetic Acid SCHEMBL6934641 0.78 MAOB (0.51) ALDH1A1MAOBMETAP1ACHECYP19A1
SCHEMBL19330670 0.78 METAP1 (0.51) ALDH1A1MAPTMAOBMAOAMETAP1
SCHEMBL19330671 0.78 METAP1 (0.51) ALDH1A1MAPTMAOBMAOAMETAP1
SCHEMBL31147657 0.78 MAPT (0.51) ALDH1A1MEN1APPMAPTSNCA
SCHEMBL356454 0.78 MAPT (0.51) ALDH1A1MEN1APPMAPTSNCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040198791-A1 Fused imidazole derivative FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-10-07 US disclosed
EP-1403256-A1 FUSED IMIDAZOLE DERIVATIVE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198791-A1 Fused imidazole derivative H1-0, H1-5, H1-3 ALDH1A1 784/4885MEN1 1176/4885APP 4697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.